Knopp Neurosciences Inc.
This article was originally published in Start Up
Executive Summary
Knopp Neurosciences is developing the right-oriented enantiomer of Parkinson's and restless leg syndrome drug pramipexole (Mirapex) for amyotrophic lateral sclerosis. The drug has received orphan designation from the FDA, and is now in Phase IIa studies in 80 ALS patients.
You may also be interested in...
First Deal Of Scangos Era Brings Phase II ALS Candidate To Biogen Idec
Big biotech pays $80 million to Knopp Biosciences for worldwide license to dexpramiprexole.
First Deal Of Scangos Era Brings Phase II ALS Candidate To Biogen Idec
Big biotech pays $80 million to Knopp Biosciences for worldwide license to dexpramiprexole.
Start-Up Previews (07/2008)
A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Glioblastoma Start-Ups Get Specific," "Glaucoma Start-Ups Reach Critical Mass," and "ALS on the Cusp." Plus these Start-Ups Across Health Care: EarlySense, NeoChord, and Pantec Biosolutions.